Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "SEC"

2373 News Found

Industry hails Union Budget 2024-25
Policy | July 23, 2024

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable


Health Minister Nadda chairs a training program for street food vendors
Policy | July 22, 2024

Health Minister Nadda chairs a training program for street food vendors

The innovative ‘Street Safe’ Rapid Testing Kit should be provided to all vendors attending the Food Safety and Certification (FoSTaC) trainings to ensure that safe food is used by the street food vendors across the country


Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval
Drug Approval | July 22, 2024

Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval

Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well


Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives
News | July 22, 2024

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23


Singhi Advisors facilitates acquisition of 85% stake of GMP Technical Solutions by Japanese Shinryo Corporation
News | July 22, 2024

Singhi Advisors facilitates acquisition of 85% stake of GMP Technical Solutions by Japanese Shinryo Corporation

This transaction is the third acquisition by three different Japanese players in this segment


Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India
News | July 19, 2024

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %


Lupin divests US commercial women's health specialty business to Evofem
News | July 17, 2024

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones


Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China
News | July 16, 2024

Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media


Merck completes acquisition of EyeBio
News | July 16, 2024

Merck completes acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret